UK health officials approve Semaglutide (Wegovy) for heart attack and stroke prevention in overweight individuals with cardiovascular disease.

UK health officials have approved weight-loss drug Semaglutide (Wegovy) for the prevention of heart attacks and strokes in overweight individuals. This marks the first weight-loss drug to be approved in the UK for a preventive treatment role in those with established cardiovascular disease. The drug can be prescribed to people with a BMI of 27 or over who have been diagnosed with cardiovascular disease. The approval comes after a study found that the drug reduced the risk of cardiovascular disease by 20%.